Table 1.
Trials baseline characteristics
| Trials | MacDonald et al 201012 | Jones et al 201313 | Hunter et al 201414 | Di Biase et al 201615 | Prabhu et al 201716 | Marrouche et al 201817 | All trials | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Groups | Ablation | Medical | Ablation | Medical | Ablation | Medical | Ablation | Medical | Ablation | Medical | Ablation | Medical | Ablation | Medical | Total | P |
| Patient numbers | 22 | 19 | 26 | 26 | 26 | 24 | 102 | 101 | 33 | 33 | 179 | 184 | 388 | 387 | 775 | |
| Mean follow‐up mo |
6 | 12 | 6 | 24 | 6 | 37.6 | 15 | |||||||||
| Male | 17 (77%) | 15 (79%) | 21 (81%) | 24 (92%) | 25 (96%) | 23 (96%) | 77 (75%) | 74 (73%) | 31 (94%) | 29 (88%) | 156 (87%) | 155 (84%) | 327 (84%) | 320 (83%) | 647 (83%) | |
| Age, y M ± SD |
62.3 ± 6.7 | 64.4 ± 8.3 | 64 ± 10 | 62 ± 9 | 55 ± 12 | 60 ± 10 | 62 ± 10 | 60 ± 11 | 59 ± 11 | 62 ± 9.4 | 64 ± 2.5* | 64 ± 2.9* | 62.1 ± 7.9 | 62.4 ± 7.7 | 62.2 ± 7.8 | 0.54 |
| LVEF, % M ± SD |
36.1 ± 11.9 | 42.9 ± 9.6 | 22 ± 8 | 25 ± 7 | 32 ± 8 | 34 ± 12 | 29 ± 5 | 30 ± 8 | 32 ± 9.4 | 34 ± 7.8 | 31.5 ± 1.7* | 32.5 ± 2.2* | 30.5 ± 6.2 | 32.1 ± 7.1 | 31.2 ± 6.7 | 0.0008 |
| LAD, mm M ± SD |
NA | NA | 50 ± 6 | 46 ± 7 | 52 ± 11 | 50 ± 10 | 47 ± 4.2 | 48 ± 4.9 | 48 ± 5.5 | 47 ± 8.2 | 48 ± 1.5 | 49.5 ± 8.3* | 48.1 ± 4.6 | 48.6 ± 7.6 | 48.3 ± 6.2 | 0.28 |
| 6MWTD, m M ± SD |
278 ± 131 | 331 ± 117 | 416 ± 78 | 411 ± 109 | NA | NA | 348 ± 111 | 350 ± 130 | 491 ± 147 | 489 ± 132 | NA | NA | 375 ± 133 | 382 ± 137 | 378.5 ± 135 | 0.62 |
| MLWHF M ± SD |
64.3 ± 15 | 54.9 ± 22.3 | 42 ± 23 | 49 ± 21 | NA | NA | 52 ± 24 | 50 ± 27 | NA | NA | NA | NA | 52 ± 23.4 | 50 ± 25.3 | 51 ± 24.3 | 0.48 |
| BNP, pn/mL M ± SD |
2550 ± 2150 | 1846 ± 1687 | 412 ± 324 | 283 ± 285 | NA | NA | NA | NA | 266 ± 210 | 256 ± 208 | NA | NA | 933 ± 1501 | 652 ± 1083 | 792 ± 1315 | 0.17 |
| AF duration before enrollment, mo M ± SD |
44 ± 36.5 | 64 ± 47.6 | 23 ± 22 | 24 ± 29 | 24 ± 4* | 27 ± 9* | 8.6 ± 3.2 | 8.4 ± 4.1 | 23 ± 18 | 21 ± 15 | NA | NA | 18 ± 21.1 | 19 ± 24.8 | 18.5 ± 23 | 0.45 |
| AF monitoring method during follow‐up | ECG and 24 h Holter monitor | ECG, 48 h Holter monitor and existing implanted devices | ECG and 48 h Holter monitor | Remote monitoring using existing implanted devices | ECG and 24 h Holter monitor and existing implanted devices | Remote monitoring using existing implanted devices | ||||||||||
| AF freedom during follow‐up, % | 10 (50%) | 0 (0%) | 22 (84%) | 0 (0%) | 19 (73%) | 0 (0%) | 73 (71%) | 37(101%) | 33 (100%) | 0 (0%) | 113 (63%) | 41 (22%) | 270 (80%) | 78 (20%) | 348 (45%) | 0.0001 |
Abbreviations: 6MTD, 6‐minute walk test distance; AF, atrial fibrillation; BNP, Beta natriuretic peptide; ECG, Electrocardiogram; LAD, Left atrial diameter; LVEH, left ventricular ejection fraction; MLWHF, Minnesota living with heart failure.* indicates that any value with * sign in table 1 is calculated from the main manuscript data.